Augmenting the Immune System to Achieve Great Outcomes in Cancer Care
March 15th 2015During the session "Principles of Immunotherapy" at the National Comprehensive Cancer Network 20th Annual Conference, Anthony J. Olszanski, RPh, MD, from the Fox Chase Cancer Center, described the complex interplay between the immune system and cancer, and some of the current immunotherapies being used today.
Read More
Dr Clifford Goodman Outlines the Pros and Cons of NCCN Guidelines
March 14th 2015Over the years, the National Comprehensive Cancer Network Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD.
Watch
Linda House Highlights the Effect of Strong Patient-Physician Relationships
March 14th 2015Patient-provider dialogue before making treatment decisions affects how satisfied patients are with their overall care, Linda House, RN, BSN, MSM, president of the Cancer Support Community, said at the National Comprehensive Cancer Network 20th Annual Conference.
Watch
NCCN Guidelines Become Resource Stratified for Global Use
March 13th 2015Resource constraints may confine the ability of physicians to deliver optimal cancer care to all patients across the world, which the National Comprehensive Cancer Network is acknowledging by resource stratifying its Guidelines.
Read More
Kim Thiboldeaux Explains the New Patient Experience in Cancer Care
March 13th 2015Patients are looking for more transparency when it comes to their treatment options so they can make informed decisions and "take control of their journey," Kim Thiboldeaux, chief executive officer of the Cancer Support Community, said at the National Comprehensive Cancer Network 20th Annual Conference.
Watch
20 Years of Creating and Embracing Guidelines in Cancer Care
March 13th 2015When the first National Comprehensive Cancer Network Guidelines were developed 20 years ago, even the participating members who were there at the beginning were skeptical they would be able to come to an agreement and build something lasting.
Read More
Transforming the NCCN Guidelines
March 12th 2015During his keynote speech at the National Comprehensive Cancer Network (NCCN)'s 20th Annual Conference, Chief Executive Officer Robert Carlson, MD, spent the majority of his time discussing the NCCN Guidelines because they are the core of its services.
Read More
Promising Results for Elotuzumab Presented at Sessions on Multiple Myeloma
December 9th 2014Monday's oral abstract sessions on multiple myeloma at the Annual Meeting of the American Society of Hematology featured final phase 1b/2 results on the elotuzumab combination that received breakthrough therapy status from FDA earlier this year.
Read More
Sessions Report Phase 2 Results on Pomalidomide Combinations
December 9th 2014Pomalidomide was approved by FDA in February 2013 for multiple myeloma patients whose disease has progressed despite having received at least 2 other therapies. On Monday, researchers at the American Society of Hematology Annual Meeting presented results of phase 2 studies on combinations with the immunomodulatory drug.
Read More
CML Updates: Defining MMR and Results of the DASISION Trial
December 9th 2014On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia included 5-year follow-up results from the DASISION trial and recognizing failure for major molecular response to guide treatment modification.
Read More
Session on Survivorship Outlines Surveillance Strategies in Non-Hodgkin Lymphoma
December 8th 2014At an education session at the American Society of Hematology Annual Meeting, Christopher R. Flowers, MD, MS, discussed current thinking in the use of routine imaging for patients who have achieved a long-term complete response in non-Hodgkin lymphoma.
Read More
Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorefenib in AML
December 8th 2014The plenary session on the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, saw the best presentations, selected by the Program Committee, from among the thousands of scientific abstracts that were accepted for the meeting. These talks included a JAK/STAT-mediated thrombopoietin regulation by the Ashwell-Morell receptor, lenalidomide-mediated casein kinase regulation in myelodysplastic syndrome, and the results of the SORAML trial in acute myeloid leukemia.
Read More
Study Suggests Method of Reducing Blood Clots Without Risking Bleeding
December 8th 2014A novel treatment method unveiled at the 56th Annual Meeting of the American Society of Hematology was among 4 important studies about reducing blood clots presented Sunday at the gathering in San Francisco.
Read More
Results Project Savings for Payers With New Oral Anticoagulants
December 7th 2014Saturday's poster session on Health Services and Outcomes research featured results projecting an overall reduction in medical costs from the use of new oral anticoagulants, and new studies about the treatment of children with sickle cell disease.
Read More
Early Treatment, Monoclonal Antibodies Discussed in Multiple Myeloma
December 7th 2014Jesus F. San Miguel, MD, PhD, of the Spanish Myeloma Group, delivered the Han-Wasserman Lecture and discussed prognostic factors that allowed his research team to give early treatment to high-risk patients, improving their survival.
Read More
Healthcare Costs in Need of Solutions: Experts at ASH Agree
December 7th 2014While medical oncologists, drug developers, and research scientists presented their research findings and novel treatment options in hematological cancers, a special session in the afternoon on the first day of the 56th Annual Meeting of the American Society of Hematology (ASH), held December 6 to 9 in San Francisco, addressed the aspect of cost of care and the increasing financial burden faced by the cancer patient.
Read More
Long-term Results of Vismodegib in Patients With Basal Cell Carcinoma Reported
November 16th 2014Final safety and efficacy results for vismodegib were reported at the Society for Melanoma Research, 2014 International Congress, for the 30-month mark of the ERIVANCE trial. The Congress is meeting November 13-16 in Zurich, Switzerland.
Read More
Oncolytic Virus Proves Promising in Advanced Melanoma
November 16th 2014Despite the various treatment advances in melanoma, advanced stages of the disease remain a significant challenge for oncologists. Novel methods of attacking disease vulnerabilities continue to be developed-one such technique is the use of oncolytic viruses to destroy cancer cells. A couple of studies presented an update on preclinical and clinical progress with CAVATAK, formulated using the common cold Coxsackievirus Type A21 (CVA21), during the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13—16.
Read More
Patients with metastatic melanoma receiving vemurafenib following disease progression showed similar or better overall response to patients without progressive disease, according to findings from an analysis reported at the 11th International Congress of the Society for Melanoma Research on November 15, 2014.
Read More
More Good News on Pembrolizumab for Melanoma Patients Without Other Options
November 16th 2014Results of a head-to-head comparison of pembrolizumab and standard chemotherapy in patients with advanced melanoma, including those who had experienced disease progression following ipilimumab, showed superior clinical response with pembrolizumab that was durable.
Read More
More Details Presented on Melanoma Diagnostic Test
November 15th 2014Much of the news at the Society of Melanoma Research, 2014 International Congress, involves breakthrough therapies for treating metastatic melanoma in its later stages. But the year has brought developments in diagnostics, too. Tools to determine which patients need aggressive treatment and which ones do not are becoming important. As awareness of melanoma grows, more patients arrive at doctors' offices with suspicious skin marks at earlier stages.
Read More
Nivolumab Shows Durable Response in Heavily Pre-treated Patients with Advanced Melanoma
November 15th 2014Nivolumab continues to show an impressive response that is both prompt and durable in patients with advanced melanoma, according to updated results from a long-term follow-up presented at the 11th International Congress of the Society for Melanoma Research on November 15, 2014.
Read More
Autophagy Regulators: An Emerging Target in Melanoma
November 15th 2014During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research.
Read More
Merck to Present Data on The First FDA-Approved PD-1 Inhibitor: Pembrolizumab
November 15th 2014As the immuno-oncology landscape intensifies, a second player in the game, Merck's PD-1 inhibitor pembrolizumab (Keytruda), was recently approved for the treatment of advanced, unresectable melanoma.
Read More
Ledipasvir-Sofosbuvir Can Improve HCV-Mediated Neurocognitive Dysfunction
November 10th 2014A late afternoon talk on the third day at The Liver Meeting 2014, evaluated the influence of some of the newer antiviral agents on "brain fog," a phenomenon quite commonly observed in hepatitis C virus-infected patients, especially among those with mild disease.
Read More